Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jac/dkaa418 http://scihub22266oqcxt.onion/10.1093/jac/dkaa418 33063117!7665526!33063117     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33063117&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33063117.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Antimicrob+Chemother 2021 ; 76 (2): 286-291 Nephropedia Template TP {{tp|p=33063117|t=2021. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis |pdf=|usr=}}{{33063117}} gab.com Text Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis JO: J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33063117 #FOAvip BACKGROUND: The combination of sofosbuvir and daclatasvir has a well-established safety profile and improves clinical outcomes in HCV patients. In silico and in vitro studies suggest that sofosbuvir/daclatasvir may show antiviral activity against SARS-CoV-2. METHODS: Three clinical trials comparing sofosbuvir/daclatasvir-based regimens with a comparator in hospitalized COVID-19 patients were combined in a meta-analysis. The primary outcomes measured were clinical recovery within 14 days of randomization, time to clinical recovery and all-cause mortality. A two-step approach was used to analyse individual-level patient data. The individual trial statistics were pooled using the random-effects inverse-variance model. RESULTS: Our search identified eight studies of which three met the inclusion criteria (n = 176 patients); two studies were randomized and one was non-randomized. Baseline characteristics were similar across treatment arms. Clinical recovery within 14 days of randomization was higher in the sofosbuvir/daclatasvir arms compared with control arms [risk ratio = 1.34 (95% CI = 1.05-1.71), P = 0.020]. Sofosbuvir/daclatasvir improves time to clinical recovery [HR = 2.04 (95% CI = 1.25-3.32), P = 0.004]. The pooled risk of all-cause mortality was significantly lower in the sofosbuvir/daclatasvir arms compared with control arms [risk ratio = 0.31 (95% CI = 0.12-0.78), P = 0.013]. CONCLUSIONS: Available evidence suggests that sofosbuvir/daclatasvir improves survival and clinical recovery in patients with moderate to severe COVID-19. However, the sample size for analysis was relatively small, one of the trials was not randomized and the designs were not standardized. These results need to be confirmed in larger randomized controlled trials. Twit Text FOAVip Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis ????J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33063117 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33063117 #FOAvip English Wikipedia <ref>{{Cite pmid|33063117}}</ref> Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis #MMPMID33063117 Simmons B; Wentzel H; Mobarak S; Eslami G; Sadeghi A; Ali Asgari A; Abbaspour Kasgari H; Tirgar Fakheri H; Merat S; Hill A J Antimicrob Chemother 2021[Jan]; 76 (2): 286-291 PMID33063117show ga BACKGROUND: The combination of sofosbuvir and daclatasvir has a well-established safety profile and improves clinical outcomes in HCV patients. In silico and in vitro studies suggest that sofosbuvir/daclatasvir may show antiviral activity against SARS-CoV-2. METHODS: Three clinical trials comparing sofosbuvir/daclatasvir-based regimens with a comparator in hospitalized COVID-19 patients were combined in a meta-analysis. The primary outcomes measured were clinical recovery within 14 days of randomization, time to clinical recovery and all-cause mortality. A two-step approach was used to analyse individual-level patient data. The individual trial statistics were pooled using the random-effects inverse-variance model. RESULTS: Our search identified eight studies of which three met the inclusion criteria (n = 176 patients); two studies were randomized and one was non-randomized. Baseline characteristics were similar across treatment arms. Clinical recovery within 14 days of randomization was higher in the sofosbuvir/daclatasvir arms compared with control arms [risk ratio = 1.34 (95% CI = 1.05-1.71), P = 0.020]. Sofosbuvir/daclatasvir improves time to clinical recovery [HR = 2.04 (95% CI = 1.25-3.32), P = 0.004]. The pooled risk of all-cause mortality was significantly lower in the sofosbuvir/daclatasvir arms compared with control arms [risk ratio = 0.31 (95% CI = 0.12-0.78), P = 0.013]. CONCLUSIONS: Available evidence suggests that sofosbuvir/daclatasvir improves survival and clinical recovery in patients with moderate to severe COVID-19. However, the sample size for analysis was relatively small, one of the trials was not randomized and the designs were not standardized. These results need to be confirmed in larger randomized controlled trials. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Aged[MESH] |Antiviral Agents/administration & dosage/*therapeutic use[MESH] |Carbamates/administration & dosage/*therapeutic use[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Humans[MESH] |Imidazoles/administration & dosage/*therapeutic use[MESH] |Iran[MESH] |Male[MESH] |Middle Aged[MESH] |Pyrrolidines/administration & dosage/*therapeutic use[MESH] |Randomized Controlled Trials as Topic[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Sofosbuvir/administration & dosage/*therapeutic use[MESH] |Treatment Outcome[MESH]Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an indi(epmc).pdf DeepDyve Pubget Overpricing